Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis

Molecular Vision

Volumn 17, Issue , 2011, Pages 932-938

  Wakamatsu, Tais Hitomi ^a   Tanaka, Mari ^b   Satake, Yoshiyuki ^c   Dogru, Murat ^a,c   Fukagawa, Kazumi ^a   Igarashi, Ayako ^c   Fujishima, Hiroshi ^d  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yatsuekimae Ajisai Eye Clinic   (Japan)

^c TOKYO DENTAL COLLEGE   (Japan)

^d TSURUMI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; TACROLIMUS;

ADOLESCENT; ADULT; ANTERIOR EYE CHAMBER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC KERATOCONJUNCTIVITIS; CHEMOSIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CORNEA; CORRELATION COEFFICIENT; DISEASE SEVERITY; DRUG EFFICACY; EYE REFRACTION; FEMALE; HEAT SENSATION; HERPES SIMPLEX KERATITIS; HUMAN; INTRAOCULAR PRESSURE; LENS; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; WILCOXON SIGNED RANKS TEST;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CHILD; CONJUNCTIVITIS, ALLERGIC; CORNEA; CORNEAL EDEMA; DRUG ADMINISTRATION SCHEDULE; EOSINOPHIL CATIONIC PROTEIN; FEMALE; FLUORESCEIN; HUMANS; JAPAN; KERATOCONJUNCTIVITIS; MALE; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; TACROLIMUS; TEARS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955571933     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology 1990; 97:992-1000. [PMID: 1976238]
2. Tuft SJ, Kemeny DM, Dart JK, Buckley RJ. Clinical features of atopic keratoconjunctivitis. Ophthalmology 1991; 98:150-158. [PMID: 2008272]
3. Dogru M, Nakagawa N, Tetsumoto K, Katakami C, Yamamoto M. Ocular surface disease in atopic dermatitis. Jpn J Ophthalmol 1999; 43:53-57. [PMID: 10197744]
4. Power WJ, Tugal-Tutkun I, Foster CS. Long-term follow-up of patients with atopic keratoconjunctivitis. Ophthalmology 1998; 105:637-642. [PMID: 9544637]
5. Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol 2010; 10:478-485. [PMID: 20720488]
6. Calder VL, Jolly G, Hingorani M, Adamson P, Leonardi A, Secchi AG, Buckley RJ, Lightman S. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy 1999; 29:1214-1222. [PMID: 10469030]
7. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol 2000; 106:1019-1032. [PMID: 11112882]
8. Foster CS, Rice BA, Dutt JE. Immunopathology of atopic keratoconjunctivitis. Ophthalmology 1991; 98:1190-1196. [PMID: 1923355]
9. Hu Y, Adan ES, Matsumoto Y, Dogru M, Fukagawa K, Takano Y, Tsubota K, Fujishima H. Conjunctival in vivo confocal scanning laser microscopy in patients with atopic keratoconjunctivitis. Mol Vis 2007; 13:1379-1389. [PMID: 17768384]
10. Ostler HB, Martin RG, Dawson CR. The use of disodium cromoglycate in the treatment of atopic ocular disease. New York: John Wiley; 1977.
11. Jay JL. Clinical features and diagnosis of adult atopic keratoconjunctivitis and the effect of treatment with sodium cromoglycate. Br J Ophthalmol 1981; 65:335-340. [PMID:6788069]
12. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 2001; 7:73-77. [PMID: 11393207]
13. Nivenius E, van der Ploeg I, Jung K, Chryssanthou E, van Hage M, Montan PG. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye (Lond) 2007; 21:968-975. [PMID: 16680103]
14. Attas-Fox L, Barkana Y, Iskhakov V, Rayvich S, Gerber Y, Morad Y, Avni I, Zadok D. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res 2008; 33:545-549. [PMID: 18600486]
15. Ohashi Y, Ebihara N, Fujishima H, Fukushima A, Kumagai N, Nakagawa Y, Namba K, Okamoto S, Shoji J, Takamura E, Hayashi K. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 2010; 26:165-174. [PMID: 20307214]
16. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46:228-241. [PMID: 11807435]
17. Reitamo S, Remitz A, Kyllonen H, Saarikko J. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol 2002; 3:381-388. [PMID: 12113647]
18. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, Schoepf E, Lahfa M, Diepgen TL, Judodihardjo H, Wollenberg A, Berth-Jones J, Bieber T, European Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109:547-555. [PMID: 11898005]
19. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, Cambazard F, Rustin M, Taïeb A, Gratton D, Sauder D, Sharpe G, Smith C, Jünger M, de Prost Y. European / Canadian Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109:539-546. [PMID: 11898004]
20. Sasakawa Y, Sakuma S, Higashi Y, Sasakawa T, Amaya T, Goto T. FK506 suppresses neutrophil chemoattractant production by peripheral blood mononuclear cells. Eur J Pharmacol 2000; 403:281-288. [PMID: 10973631]
21. Kyllönen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004; 150:1174-1181. [PMID:15214906]
22. Ezeamuzie CI. Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. Int J Immunopharmacol 1996; 18:263-270. [PMID: 8894806]
23. Peterson LB, Cryan JG, Rosa R, Martin MM, Wilusz MB, Sinclair PJ, Wong F, Parsons JN, O'Keefe SJ, Parsons WH, Wyvratt M, Sigal NH, Williamson AR, Wiederrecht GJ. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. Transplantation 1998; 65:10-18. [PMID: 9448137]
24. Reitamo S, Wollenberg A, Schöpf E, Perrot JL, Marks R, Ruzicka T, Christophers E, Kapp A, Lahfa M, Rubins A, Jablonska S, Rustin M. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136:999-1006. [PMID: 10926735]
25. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Longterm safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44:S58-S64. [PMID: 11145796]
26. Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003; 135:297-302. [PMID: 12614745]
27. Mayer K, Reinhard T, Reis A, Bohringer D, Sundmacher R. FK 506 ointment 0.1% - A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients. Klin Monatsbl Augenheilkd 2001; 218:733-736. [PMID: 11731901]
28. Tomassini M, Magrini L, Bonini S, Lambiase A. Increased serum levels of eosinophil cationic protein and eosinophilderived neurotoxin (protein X) in vernal keratoconjunctivitis. Ophthalmology 1994; 101:1808-1811. [PMID: 7800361]
29. Leonardi A, Borghesan F, Faggian D, Secchi A, Plebani M. Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis. Allergy 1995; 50:610-613. [PMID: 8588697]
30. Montan PG, van Hage-Hamsten M. Eosinophil cationic protein in tears in allergic conjunctivitis. Br J Ophthalmol 1996; 80:556-560. [PMID: 8759270]
31. Leonardi A, Borghesan F, Faggian D, Depaoli M, Secchi AG, Plebani M. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol 2000; 129:151-158. [PMID: 10682966]
32. Hogan MJ. Atopic keratoconjunctivitis. Am J Ophthalmol 1953; 36:937-947. [PMID: 13065376]
33. Shimmura S, Ono M, Shinozaki K, Toda I, Takamura E, Mashima Y, Tsubota K. Sodium hyaluronate eyedrops in the treatment of dry eyes. Br J Ophthalmol 1995; 79:1007-1011. [PMID: 8534643]
34. van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol 1969; 82:10-14. [PMID: 4183019]
35. Tanaka M, Dogru M, Takano Y, Miyake-Kashima M, Asano- Kato N, Fukagawa K, Tsubota K, Fujishima H. The relation of conjunctival and corneal findings in severe ocular allergies. Cornea 2004; 23:464-467. [PMID: 15220730]
36. Nishino K, Fukushima A, Okamoto S, Ohashi Y, Fukata K, Ozaki A, Ueno H. Suppression of experimental immunemediated blepharoconjunctivitis in Brown Norway rats by topical application of FK506. Graefes Arch Clin Exp Ophthalmol 2002; 240:137-143. [PMID: 11931080]
37. Sengoku T, Sakuma S, Satoh S, Kishi S, Ogawa T, Ohkubo Y, Mutoh S. Effect of FK506 eye drops on late and delayed-type responses in ocular allergy models. Clin Exp Allergy 2003; 33:1555-1560. [PMID: 14616868]
38. Whitcup SM, Pleyer U, Lai JC, Lutz S, Mochizuki M, Chan CC. Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocul Immunol Inflamm 1998; 6:51-56. [PMID: 9798194]